Conference Coverage

VIDEO: True remission necessary before tapering or discontinuing RA drugs


 

AT RWCS 2015

References

MAUI, HAWAII– Discontinuing medications when rheumatoid arthritis patients are doing well is a hot topic in rheumatology lately, but it’s tricky.

The idea is to give patients a break from the costs and side effects of steroids, methotrexate, and biologics. Whether or not doing so is a good idea has a lot to do with how you define remission, and the odds of recapturing patients if they flare.

Advice from Dr. Roy Fleischmann, a clinical professor of rheumatology at the University of Texas Southwestern Medical Center in Dallas, might help. At the 2015 Rheumatology Winter Clinical Symposium, he shared his know-how about tapering and discontinuing treatments, culled from his professional experience and the literature on the subject in a video interview.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

aotto@frontlinemedcom.com

Recommended Reading

Reducing abatacept feasible for poor-prognosis early RA patients
MDedge Family Medicine
MRI shows ongoing inflammation despite clinical remission in early RA
MDedge Family Medicine
RA clinical remission possible with half etanercept dose
MDedge Family Medicine
Consider Chikungunya virus in new-onset polyarthritis
MDedge Family Medicine
RA risk lowered by recent gastrointestinal and urogenital infections
MDedge Family Medicine
Acute RA flares increase risk of cardiovascular disease
MDedge Family Medicine
New concerns rise over iatrogenic hydroxychloroquine retinopathy
MDedge Family Medicine
VIDEO: As biosimilars arrive in U.S., treatment questions arise
MDedge Family Medicine
Rituximab for RA: Think like a European
MDedge Family Medicine
What’s new with methotrexate for rheumatoid arthritis
MDedge Family Medicine